抗生素,质子抑制剂,NSAIDs和肝脏之间的关联
Hon-Yen Wu1, Chun-Ru Hsu2, Ping-Hsiu Tsai3
1Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei City, Taiwan.
质子抑制剂 (PPI),非类固醇抗炎药物 (NSAID) 和某些抗生素与肝 (LA) 的更高风险有关. 这表明,需要谨慎使用这些药物,以防止LA的发展.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 由Klebsiella pneumoniae引起的肝 (LA) 是台湾的一个重大公共卫生问题.
- 了解风险因素,包括药物使用,对于LA的预防和管理至关重要.
研究的目的:
- 调查使用抗生素,质子抑制剂 (PPI) 和非类固醇抗炎药物 (NSAID) 与因肝而入院的风险之间的关联.
- 为了澄清药物暴露和LA诊断之间的时间关系.
主要方法:
- 一项基于人口的病例控制研究,利用台湾国家健康保险数据库 (2000-2021).
- 使用倾向分数匹配 (PSM) 来创建一个没有LA的对照组,根据年龄和性别进行匹配.
- 后勤回归分析评估了诊断前一年内药物暴露的几率比率 (ORs) 和95%置信区间 (CI).
主要成果:
- 这项研究分析了10,335名LA患者和20,670名对照组.
- 在LA和最近使用第二代/3代头素 (OR 181.91),NSAIDs (OR 17.0),阿莫西西林/阿米西林与β-乳糖酶抑制剂 (OR 15.0),PPI (OR 9.5) 和诺基诺 (OR 9.2) 之间发现了显著的关联.
- 在住院治疗前,NSAID,第二代/第三代头素和阿莫西西林/西林与β-乳糖酶抑制剂的关联持续了长达一年.
结论:
- 质子抑制剂 (PPI),非类固醇抗炎药物 (NSAID) 和特定抗生素与肝脏的风险增加显著相关.
- 这些发现凸显了需要仔细考虑在患有肝风险或出现肝的患者中使用药物的必要性.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...


